Nostril swab best way to test for COVID-19, study finds

Nasopharyngeal swabs – taken from far back inside the nostril – were found to be more effective at detecting COVID-19 than saliva tests or swabs just inside the nostril or under the tongue.

College of Veterinary Medicine celebrates graduating students

Graduating students with the Cornell University College of Veterinary Medicine celebrated with family, friends, faculty and staff at commencement week events.

Around Cornell

Futile veterinary care is widespread, study finds

More than 99% of 474 veterinarians surveyed said they’d encountered useless or nonbeneficial veterinary care in their careers, according to a new Cornell-led study that documents the prevalence of futile care for the first time.

Higher dengue rates found near public transit in low-income areas

In Medellin, Colombia, low-income residents who lived in close proximity to new public transit stations had increased rates of mosquito-transmitted dengue fever, according to a new study.

Discovery offers starting point for better gene-editing tools

In new research, Cornell scientists define with atomic precision how a transposon-derived system edits DNA in RNA-guided fashion. 

Mong fellowship advances neuroimaging collaboration

The discovery made by two doctoral students could have future implications for human health, setting a path for research into understanding brain function.

A Q&A with Dr. Sarah Robbins of the Veterinary College

Dr. Sarah Robbins joined the College of Veterinary Medicine as assistant clinical professor in the Section of Emergency and Care.

Around Cornell

Experts develop genetic test to predict severe digestion disorder in dogs

Scientists at the College of Veterinary Medicine are one step closer to understanding the genetic predispositions behind congenital idiopathic megaesophagus.

Around Cornell

Startup Roundup: Antithesis Foods, Guard Medical, C2i, Bactana

Cornell startup Antithesis Foods and Bactana were awarded NSF small-business grants, as Guard Medical raises $11 million in Series B investments and C2i launches a disease test in Europe.